Table 6.

Changes in 25(OH)D Levels with Regards to VDR Polymorphism in Breast Cancer Patients

Genotype	Placebo				Vitamin D				Absolute treatment effecta
	n	Baseline	8 week follow up	pc	n	Baseline	8 week follow up	pc	placebo	Vitamin D	Pb
FokI
FF	2	9.4±3.7	10±3.2	0.18	7	28.5±15	25.0±0	0.082	0.6±0.6	-3.5±15.5	0.83
Ff	19	14.8±2.3	13±2.2	0.003	19	28.1±2.9	39.3±4.0	0.007	-1.8±1.1	11.2±3.3	0.001*
ff	3	17.0±0	14.0±4	0.43	2	27.0±7.0	49.5±6.5	0.015	-3±4	22.5±0.5	0.024*
BsmI
BB	5	15.8±5.8	12.2±5.7	0.82	2	25.5±14	21.0±5.0	0.4	-3.6±1.4	-4.5±19.5	0.93
Bb	11	11.3±2.4	11.4±2.4	0.003	16	27.4±3.0	39.0±4.3	0.003	0.09±1.4	11.6±2.9	0.002*
bb	8	17.5±3	14.7±3.1	0.4	4	35.5±6.4	46.2±9.0	0.82	-2.8±1.6	10.7±9.6	0.26
ApaI
AA	11	15.3±3.4	13.5±3.1	0.012	9	35.1±4.4	45.8±7	0.087	-1.8±1.2	10.7±5	0.038*
Aa	11	12.5±1.8	10.9±1.9	0.053	9	24.5±4.2	31.0±3.9	0.26	-1.6±1.6	6.5±4.6	0.089
aa	2	18.0±12.0	17.5±12.	0.12	5	21.8±2.3	41.0±5.8	0.073	-0.5±0.5	19.2±7.5	0.07
TaqI
TT	5	18.4±5.7	15.6±4.6	0.11	4	31±5.6	46.2±9.0	0.05	-2.8±2.35	14.7±4.3	0.007*
Tt	15	14.6±2.3	14.0±2.3	0.001	13	27±4.1	38.3±5.2	0.032	-0.6±15.3	11.3±4.2	0.017*
tt	3	8.6±2.4	3.6±0.8	0.14	6	28.1±3.6	35.7±5.6	0.43	-5.0±3.0	7.6±7.8	0.31

Values are Mean±SD;

^*, p value< 0.05;

^a, Absolute treatment effect is the absolute change from baseline to follow-up in the treatment group minus the absolute change from baseline to follow-up in the placebo group;

^b, P values for difference between treatment and placebo groups;

^c, P values for difference between follow-up and baseline visits.